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The C-3' quaternary ammonium cephems belong to group IV of the microbiological classification of cephalosporins. This 
group is divided into two subgroups according to the position of the quaternary ammonium moiety (C-3 or C-7). 
These compounds are structurally related to the third-generation cephalosporins (or group 111 of the microbiological 
classification), but in addition are featured with two or more of the following properties: broad-spectrum activity including 
Pseudomonas aeruginosa; activity against Enterobacteriaceae producing type 1 p-lactamase; the presence of a quaternary 
moiety. The zwitterionic properties of the C-3' quaternary cephalosporins allow rapid penetration through the outer 
membrane of Gram-negative bacteria, stability to and low affinity for type 1 j3-lactamases in the periplasmic space and high 
affinity for the penicillin binding proteins (PBPs). Among the currently available analogues cefpirome and cefozopran 
exhibit a well-balanced antibacterial spectrum against Gram-negative bacilli and Gram-positive cocci. Cefepime is less 
active against Staphylococcus aureus. 
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INTRODUCTION 
Since cephalothin and cephaloridine were introduced 
in 1964, cephalosporins have become a widely used 
and rapidly expanding class of antibacterial agents. A 
large number of derivatives have been synthesized by 
moditjring the 7-amino-cephalosponnic-acid (7 ACA). 
In recent years a number of highly active cephem 
derivatives have been reported, and some of them 
developed and introduced into clinical practice. 
Many of the currently marketed injectable 
cephalosporins, such as cefotaxime, ceftriaxone or 
cefiazidime have the common feature of a 2-amino- 
5-thiazolyl-acetamido group at the 7-p position of the 
cephem nucleus. They show excellent activity against 
Gram-negative bacilli, except Pseudomonas aerugiuosa, 
and moderate activity against Staphylococcus aureus 
isolates susceptible to oxacillin and methicillin (MSSA). 
The wide-spread use of these agents was followed 
by the emergence of resistant mutant strains of 
microorganisms such as Enterobacter cloacae, Serratia 
marcescens and P. aeruginosa which constitutively 
produced high level of type 1 p-lactamases. One of 
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the most apparent defects of these compounds is the 
lack of activity against Enterobacteriaceae producing 
derepressed AmpC enzymes [ 11. 
Despite the number of cephalosporins and other 
antibacterial agents available, the treatment of patients 
with severe infections remains a common problem in 
daily clinical practice. Any progress should therefore 
be welcomed. 
Among significant advances, the recent introduction 
of a positively-charged substituent at the C-3' position 
of the  cephem nucleus has overcome certain 
short-comings of earlier 2-amino-5-thiazolyl 
cephalosporins includmg activity against P. aeuttginosa and 
Gram-negative bacilli producing type 1 P-lactamases. 
NOVELTIES IN THE FIELD OF CHEMICAL STRUCTURES 
The substituent at the C-3 position and the side chain 
at the 7-p position of the cephem nucleus are key 
functions to alter the antibacterial activity. Extensive 
modifications of the 7-p acylamido side chain in 
combination with the C-3 substitution has led to 
many useful cephalosporin drugs. 
A significant step in the advance of the chemistry 
of cephalosporins was the introduction of the 
2-amino-5-thiazolyl nucleus. The combination of this 
moiety with the syn (Z)-methoxyiniino chain found 
in cefuroxime gave rise to the new so-called third- 
generation cephalosporins of which cefotaxime was 
the lead compound [2]. The introduction of the 
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2-amino-5-thiazolyl moiety greatly enhances the 
antibacterial activity against Gram-negative bacilli. The 
addition of the syn (Z)-methoxyimino residue enhanced 
the stability to broad spectrum p-lactamase hydrolysis. 
After the discovery of cefotaxime, one of the aims 
of research in the field of cephalosporins was to mo&@ 
the C-3 heterocyclic moiety to increase the plasma half- 
life. This target was reached with the synthesis of 
cefiriaxone [3]. Many of the earlier compounds have 
a N-methyl-tetrazol thio at the C-3 position of the 
cephem nucleus which was found to give rise to 
problems of disulfiram-like reactions and coagulation 
abnormalities in man. 
The goal of the research in the field of 
cephalosporins was to improve the antibacterial activity 
against P. aeruginosa, S. aureus and other Gram-positive 
cocci and Gram-negative bacilli producing type 1 
p-lactamases. Cefsulodin and ceftazidime were the 
first cephalosporins with improved activity against 
P. aeruginosa to be used in this clinical setting. They 
bear a 1-pyridinium group at the C-3 position. This 
observation prompted the researchers to prepare a 
new series of cephalosporins with a 
2-amino-5-thiazolyloxiimino chain at the 7-P-position 
and a positively charged group at C-3 (azolium 
group). Most of the C-3' quaternary ammonium 
cephems are characterized by a condensed azolium 
moiety except for cefluprenam (Figure 1). 
All these derivatives are zwitterionic compounds 
and have no net charge, since the negative charge of 
the carboxylic acid group is (internally) neutralized 
(compensated for) by the positive c'harge of the 
C-3' quaternary ammonium group. 
Ceftazidirne is the earlier member of the oxi- 
imino-2-amino-5-thiazolyl quaternary ammonium 
cephalosporins. Other cephalosporins contain a C-3' 
pyridinium such as cefsulodin, cefpimizole or 
cephaloridine, but none of them possess a 2-amino-5- 
thiazolyl moiety. Ceftazidime is a dianionic 
cephalosporin, in contrast to other compounds (e.g. 
cefpirome and cefepime) which are zwitterionic 
derivatives. 
Cefiazidime contains a carboxypropyloxiimino 
substituent attached to the acetyl chain. This additional 
carboxylic group provides acidic (negative charge) 
properties to this compound. The carboxylate anion 
of the cephem ring is neutralized by the positively 
charged quaternary ammonium group. The extra 
negative charge strongly influences the biological 
properties of ceftazidime (Figure 2). 
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Figure 1 Structure of C-3' quaternary ammonium cephenis 
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Modifications of the 2-amino-5-thiazolyl ring 
have been performed. It was found that substitution of 
the thiazolyl ring with a chlorine atom increased the 
antibacterial activity against P. aeruginosa, whereas the 
activity against other Gram-negative bacilli decreased. 
Introduction of a 5-amino-2-thiadiazolyl nucleus 
instead of a 2-amino-5-thiazolyl ring enhanced the 
antipseudomonal activity but slightly decreased the 
overall activity against Enterobacteriaceae [4]. 
Studies have demonstrated that analogues bearing 
an hydroxyimino residue exhibit higher activity 
against S .  aureus, but they are less active against Gram- 
negative bacteria than their methoxyimino counterparts. 
Introduction of a monofluoromethoxyimino group 
at the 7-position led to a two-fold increase in activity 
against most bacteria as compared with the 
methoxyimino counterpart (cefluprenam). 
Among all the C-3' quaternary ammonium 
cephalosporins, only a few of them, such as cefpirome, 
cefepime and cefozopran were introduced into 
clinical practice. A number of compounds are in 
clinical development in Japan, such as cefclidin, 
cefluprenam and cefoselis. In the field of C-3' 
quaternary ammonium cephems, research continues in 
order to overcome the production of extended- 
spectrum p-lactamases by Enterobacteriaceae, to 
increase the antipseudomonal activity and to try to 
obtain compounds active against methicillin-resistant 
isolates of S. aureus. 
Extended-spectrum P-lactamases are recognized 
for their abilities to provide resistance to cefotaxime, 
ceftriaxone, ceftazidime and aztreonam and to some 
extent to C-3' quaternary ammonium cephalosporins. 
However, MIC values for cefpirome or cefepime 
to TEM-type enzyme producing Enterobacteriaceae 
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Figure 2 Structure of dianionic and zwitterionic 
cephalosporins 
are 5 8 mg/L, but these compounds are less stable to 
the hydrolysis by SHV-type enzynies (MIC values 
I 16 mg/L) except for SHV-5 (MIC 2-4 mg/L) [5]. 
Substitution by catechol or pyridone moities gives rise 
to a new wave of cephalosporins which are stable to 
hydrolysis by these enzymes, such as RU 59863 [6]. 
NOVELTIES IN THE FIELD OF MECHANISM OF ACTION 
The effectiveness of cephalosporins against Gram- 
negative bacilli is due to a combination of the ability 
to penetrate the outer membrane, the stability to 
p-lactamase hydrolysis in the periplasmic space, and 
affinity for penicillin binding proteins (PBPs). 
Nikaido et al. [7], using proteoliposome, 
demonstrated that cefclidin, cefpirome and cefepinie 
penetrated the porin channel of Exherichia coli and 
E .  cloacae more rapidly than did ceftazidime. Yoshimura 
et al. [8] showed that the C-7-p methoxyiniino residue 
decreases the rate of penetration of monoanionic 
cephalosporins by a factor of 2 10, through the outer 
membrane into the OmpF porin of E .  coli. Non-2- 
amino-5-thiazolyl quaternary ammonium cephalosporins 
are hydrolysed at low concentrations (I 10 pM) of type 
1 p-lactamases [9]. Type 1 p-lactaniases hydrolyse these 
cephalosporins (cefpirome, cefepime, cefclidin) more 
slowly than did the earlier compounds at low substrate 
concentrations. 
Cefpirome, cefepime and cefclidin share low 
affinities or high Kin values for type 1 0-lactamases and 
would be expected to be hydrolysed slowly in vivo 
[10,11]. It has been shown that cefpirome, cefepime, 
cefclidin, and ceftazidime share a high affinity for PBP 3 
of E. coli K-12 [12]. 
CLASSIFICATION OF C-3' QUATERNARY AMMONIUM 
CEPHALOSPORINS 
Cephalosporins belong to a complex class of p-lactam 
antibiotics. Numerous classifications have been 
proposed: chemical [13], pharmacokinetic [14], 
biological [I51 and microbiologcal [I 51. 
Wi th in  the  microbiological classification, 
cephalosporins could be divided into six groups. 
Groups 111, IV and V represent the broad-spectrum 
cephalosporins, while the C-3' quaternary ammonium 
cephalosponns belong to group IV. This group of 
compounds can be divided into two subgroups, 
according to the position (C-3 or C-7) ofthe quaternary 
ammonium chain (Figure 3). 
Group IV-1 C-7 quaternary ammonium cephalosporins 
Few compounds have been designed in this subgroup. 
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Three derivatives of this series, L-640876, L-642946, 
and L-652813 bind preferentially to PBP 2 of E. coli. 
Group IV-2 C-3' quaternary ammonium cephalosporins 
These derivatives have been divided into two classes 
according to the aryl substituent at C-7: 2-amino-5- 
thiazolyl or 5-amino-2-thiadiazolyl nucleus. 
Group IV-2A 2-aminod-thiazolyl derivatives 
Numerous compounds were described but only 
ceEpirome and cefepime were introduced into clinical 
practice. All these compounds contain a syn 
alkoxyimino moiety at C-7. Cefpirome contains a 
cyclopentenopyridinium group at the C-3' position. 
Cefepime has a N-methylpyrrolidinium group at the 
C-3' position. Cefoselis (FK 037) is currently under 
development in Japan and cefquinone (HR 111) is 
used in veterinary medicine. 
Group lV-26 5-amino-2-thiadiazolyl derivatives 
Two compounds are under development in Japan: 
cefclidin, which contains a 4-carbamoyl-l- 
quinuclidinium moiety. Cefluprenam has an original 
chemical structure with a fluoromethoxyimino 
moiety at C-7 and a propenyl side chain at C-3. 
Cefozopran with an imidazolopyridium was recently 
introduced in clinical practice. 
DEFINITION OF GROUP IV CEPHALOSPORINS 
Group IV covers molecules that differ in their chemical 
structure and antibacterial activity. Cephems, which 
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Figure 3 Structure of C-3' and C-7 quaternary ammonium 
cephems. 
belong to group IV possess two or more of the following 
characteristics: the presence of a C-3' quaternary 
ammonium side chain and are zwitterionic compounds; 
a broad antibacterial spectrum including P. aertrginosa; 
good antibacterial activity against Enterobacteriaceae 
isolates producing type 1 p-lactamases such E. cloacae, 
S. rnarcescens or Citrobacterfreundii. They have to fulfil 
the definition of group I11 [14,16]. 
NOVELTIES IN ANTIBACTERIAL ACTIVITIES 
All the C-3' quaternary compounds introduced for 
clinical use or under development possess the same 
antibacterial activity as cefotaxime, but they differ by 
adding antipseudomonal activity [17,18]. There are 
differences, however, among these compounds: cefclidin 
is twice as active as ceftazidime against P. aeruginosa, 
but cefepime and cefpirome are two-fold less active 
than ceftazidime against P. aeruginosa (Figure 4). 
Compared to ceftazidime these compounds are more 
active against Enterobacteriaceae producing type 1 
p-lactamases such as S.  rnarcescens, C.freundii, E .  cloacae, 
E. coli, Providencia and M .  rnovganii (MIC,, 5 8 mg/L) 
which are resistant to ceftazidime (Table 1) [18]. 
Studies have shown that ceeirome generates significant 
p-lactamase induction less frequently than ceftazidime 
against E. cloacae. Cefpirome has been shown to select 
derepressed mutants in vitro and in vivo to a lesser 
extent than ceftazidime [ 171. 
Against S.  pneurnoniae, the most active compound 
within the C-3' quaternary ammonium cephems was 
cefpirome, whatever the resistance phenotype to 
Figure 4 Activity of C-3' quaternary ammonium cephems 
against P. aeuuginosa. From Le Noc et al. (181. 
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penicillin G of the pneumococci isolates [ZY]. Against 
penicillin-resistant isolates, cefepime and cefozopran 
exhibit equivalent activity to cefotaxime. 
Cefluprenam was weakly active and cefclidin is 
inactive (Figure 5). 
Against S .  awecis isolates susceptible to oxacillin, 
cefpirome was the most active compound. It was three 
times more active than cefozopran and cefluprenam 
and eight-times more active than cefepime. Ceftazidime 
was poorly active and cefclidin was inactive (Figure 6). 
CONCLUSION 
C-3' quaternary ammonium cephalosporins belong to 
group IV of the niicrobiologcal classification. Their 
chemical structure is innovative and the azolium part 
as well as the 2-amino-5-thiazolyl ring and the oxime 
residue, constitute the backbone of all novel series of 
cephalosporin derivatives. Due to the C-3' azolium part 
they have an orignal mecharllsni of actioii. Furthermore, 
they have overcome bacterial resistance by stability to 
and low affinity for cephalosporinases. 
Among the available C-3' quaternary ammonium 
cephalosporins, cefpirome followed by cefozopran have 
a well-balanced antibacterial spectrum including Grarn- 
positive cocci and Gram-negative bacilli. The activity 
against enterococci is more controversial. Cefpirorne 
exhibits in vitro activity against E.faecalis but not against 
E .  faecitrm. Cefepime exerts an overall higher activity 
than cefluprenam except against S .  aweu- .  Cefclidin is 
the most active derivative against Gram-negative bacilli, 
but it is ineffective against Gram-positive cocci. Cefoselis 
shares the same antibacterial activity as cefozopran. 
The main aim of the preparation of these molecules 
was for microbiological advantages. All of them show 
approximately the same pharmac-okinetic profile. They 
have an apparent elimination half-life of two hours 
and are mainly eliminated unchanged in  urine. 
Table 1 In vitro activity of C-3' quaternary ammonium cephalosporin against Enterobacteriaceae 
Cefpirome Cefepime Cefozopran Cefclidiiie Cefluprenani Ccftazidinie 
Susceptible 0.03 0.06 0.12 0.1s 0.07 0.10 
Class IV P-lactamases 0.03 0.03 0.0V 0.1s 0.00 0.12 
Clasc I hyperproduced 0.80 0.60 1 .so 0.08 1.10 40 .oo 
Extended-spectrum 1.40 1.20 2.70 1.60 7.01) 11 .00 
P-lactaniascs 
Class 111 P-lactaiiiases 0.03 0.08 0.1 1 0.22 0.09 0 .  14 
Adapted from Le Noc et al. [ls]. 
I 
Figure 5 Activity of C-3' quaternary ammonium cephems 
against S.  pneumoniae. From FrCmaux et al. [19]. 
Figure 6 Activity of C-3' quaternary ammonium cephems 
against 5'. uurcus. From Le Noc et al. [ l X J .  
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